Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02046174 · ClinicalTrials.gov registry record · Phase 2
Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared to Best Supportive Care in Colorectal Cancer Patients
A Phase 2 study, sponsored by The Rogosin Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT02046174 is a Phase 2 study that has completed, run by The Rogosin Institute. The registered enrollment target is 70 participants.
The verdict
NCT02046174, a Phase 2 study, has completed, sponsored by The Rogosin Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This is a clinical research study of an investigational (FDA IND-BB 10091) treatment for patients with advanced colorectal cancer that no longer responds to standard therapies. The treatment is being evaluated for its effect on tumor growth. It consists of the placement (implantation) of small beads that contain mouse renal adenocarcinoma cells (RENCA macrobeads). The cells in the macrobeads produce substances that have been shown to slow or stop the growth of tumors in experimental animals and veterinary patients. It has been tested in 31 human subjects with different types of cancers in a Phase I safety trial. Phase II studies in patients with colorectal, pancreatic or prostate cancers are in progress
Interventions
- BIOLOGICAL RENCA macrobeads
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2014-04-03 |
| Est. Completion | 2018-10-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02046174
The ClinicalTrials.gov registry entry for NCT02046174 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Rogosin Institute, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RENCA macrobeads is the first listed.
NCT02046174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02046174 about?
NCT02046174 is a clinical study titled "Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared to Best Supportive Care in Colorectal Cancer Patients". This is a clinical research study of an investigational (FDA IND-BB 10091) treatment for patients with advanced colorectal cancer that no longer responds to standard therapies. The treatment is being evaluated for its effect on tumor growth. It consists of the placement (implantation) of small bead...
What is the current status of trial NCT02046174?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2014-04-03. Estimated completion is 2018-10-22.
What interventions are being tested in trial NCT02046174?
The interventions under investigation include: RENCA macrobeads (BIOLOGICAL).
Who is sponsoring clinical trial NCT02046174?
This trial is sponsored by The Rogosin Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.